YMAB Historical Income Statement
| YMAB Stock | USD 9.77 0.24 2.40% |
Historical analysis of Y MAbs income statement accounts such as Interest Expense of 821.4 K, Selling General Administrative of 33.2 M, Total Revenue of 89.1 M or Gross Profit of 77.1 M can show how well Y mAbs Therapeutics performed in making a profits. Evaluating Y MAbs income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Y MAbs's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Y mAbs Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Y mAbs Therapeutics is a good buy for the upcoming year.
YMAB |
About YMAB Income Statement Analysis
Y mAbs Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Y MAbs shareholders. The income statement also shows YMAB investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Y MAbs Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Y mAbs Therapeutics. It is also known as Y MAbs overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Y MAbs' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Y mAbs Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At present, Y MAbs' Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 77.1 M, whereas Interest Expense is forecasted to decline to about 821.4 K.
| 2023 | 2024 (projected) | Depreciation And Amortization | 735K | 540.3K | Interest Income | 687.7K | 979.4K |
Y MAbs income statement Correlations
Click cells to compare fundamentals
Y MAbs Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Y MAbs income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 2.0M | 598K | 1.9M | 757K | 870.6K | 821.4K | |
| Selling General Administrative | 19.5M | 44.8M | 54.6M | 60.9M | 44.5M | 33.2M | |
| Gross Profit | (166K) | 18.5M | 32.4M | 57.7M | 73.4M | 77.1M | |
| Other Operating Expenses | 83.0M | 138.5M | 150.3M | 160.1M | 110.5M | 99.3M | |
| Operating Income | (83.0M) | (119.9M) | (115.4M) | (94.8M) | (25.7M) | (27.0M) | |
| Net Income From Continuing Ops | (81.0M) | (119.3M) | (55.3M) | (95.6M) | (19.3M) | (20.2M) | |
| Ebit | (83.0M) | (119.9M) | (115.4M) | (94.8M) | (26.4M) | (27.7M) | |
| Research Development | 63.5M | 93.7M | 93.2M | 91.6M | 54.2M | 63.1M | |
| Ebitda | (82.8M) | (119.5M) | (114.7M) | (94.0M) | (25.7M) | (27.0M) | |
| Cost Of Revenue | 166K | 2.2M | 2.5M | 7.6M | 11.4M | 12.0M | |
| Total Operating Expenses | 83.0M | 138.5M | 147.8M | 152.5M | 99.1M | 96.3M | |
| Income Before Tax | (81.0M) | (119.3M) | (55.3M) | (95.6M) | (20.9M) | (21.9M) | |
| Total Other Income Expense Net | 2.0M | 598K | 60.2M | (757K) | 4.8M | 9.2M | |
| Net Income Applicable To Common Shares | (81.0M) | (119.3M) | (55.3M) | (95.6M) | (86.0M) | (90.3M) | |
| Net Income | (78.9M) | (118.3M) | (56.3M) | (96.3M) | (21.4M) | (22.5M) | |
| Income Tax Expense | (2.1M) | (994K) | 1.1M | 757K | 561K | 589.1K | |
| Reconciled Depreciation | 166K | 396K | 782K | 839K | 804K | 473.9K | |
| Net Interest Income | 2.0M | 598K | (1.9M) | (757K) | 4.7M | 4.9M | |
| Depreciation And Amortization | 166K | 396K | 782K | 839K | 735K | 540.3K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.53) | Revenue Per Share 1.921 | Quarterly Revenue Growth (0.1) | Return On Assets (0.12) | Return On Equity (0.25) |
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.